Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831855 · ClinicalTrials.gov registry record · Phase 4
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 694
- Enrollment target
NCT02831855 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 694 participants.
The verdict
NCT02831855, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 694 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their stable dose of methotrexate treatment.
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 694 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02831855
The ClinicalTrials.gov registry entry for NCT02831855 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 694 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02831855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02831855 about?
NCT02831855 is a clinical study titled "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis". This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their s...
What is the current status of trial NCT02831855?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 694 participants. The study started on 2016-09-01. Estimated completion is 2018-12-17.
What interventions are being tested in trial NCT02831855?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT02831855?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.